Consumer Health, Eighth Edition
References for Chapter 15
Cardiovascular Disease

  1. American Heart Association. Heart Disease and Stroke Statistics—2005 Update. Dallas, 2005, The Association.
  2. He J and others. Passive smoking and the risk of coronary heart disease—A meta-analysis of epidemiologic studies. New England Journal of Medicine 340:920–926, 1999.
  3. Willett WC and others. Coffee consumption and coronary heart disease in women: A ten-year follow-up. JAMA 275:458–462, 1996.
  4. Triglycerides and heart disease. Harvard Heart Letter 11(1):1–5, 2000.
  5. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 263:1795–1801, 1990.
  6. Unal B and others. Life-years gained from modern cardiological treatments and population changes in England and Wales, 1981-2000. American Journal of Public Health 95:103–108, 2005.
  7. Castelli WP and others. Incidence of coronary heart disease and lipoprotein cholesterol levels—the Framingham Study. JAMA 256:2835–2838, 1986.
  8. Anderson KM and others. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 257:2176–2180, 1987.
  9. Samuelson O and others. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA 258:1768–1776, 1987.
  10. Gotto AM Jr and others. The cholesterol facts—a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Dallas, 1990, American Heart Association.
  11. Lipid Clinics Research Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary artery disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351–374, 1984.
  12. Danesh J and others. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082–1085, 2000.
  13. Maher VM and others. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274:1771–1774, 1995.
  14. Ridker PM and others. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269–1273, 1995.
  15. Boushey CJ and others. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274:1049–1057, 1995.
  16. Toole JF. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 91:565–575, 2004.
  17. Grundy SM and others. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 01-3670. Washington, D.C., 2001, Supt. of Documents.
  18. Grundy SM and others. Implications of recent clinical trials for the National Cholesterol Education Program Adult Panel III guidelines. Circulation 110:227–239, 2004.
  19. Barnard RJ. Effects of life-style modification on serum lipids. Archives of Internal Medicine 151:1389-1394, 1991.
  20. Mirkin G, Rich D. Fat Free, Flavor Full. Boston, 1995, Little, Brown and Company.
  21. Newman B, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 275:55–60, 1996.
  22. Dalen JE, Dalton WS. Does cholesterol lowering cause cancer? JAMA 275:67–68, 1996.
  23. Cooper GR and others. Blood lipid measurements: Variations and practical utility. JAMA 267:1652–1660, 1992.
  24. Lichtenstein AH. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease: A statement for health professionals. Circulation 95:2588–2590, 1997.
  25. Food labeling: Trans fatty acids in nutrition labeling, Nutrient content claims, and health claims; Proposed rule. Federal Register 64:62745–62825, 1999.
  26. Rimm EB and others. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 275:447–451, 1996.
  27. Gillman MW and others. Protective effects of fruits and vegetables on development of stroke in men. JAMA 273:1113–1117, 1995.
  28. Step By Step: Eating to Lower Your High Blood Cholesterol. NIH Publication No. 94-2920. Washington, D.C., 1994, Supt. of Documents.
  29. Kraus RM and others. AHA dietary guidelines, revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102:2284–2299, 2000.
  30. USDA Food composition data. USDA Nutrient Data Laboratory Web site, accessed May 23, 2005.
  31. Kantor MA. Nutrition, cholesterol and heart disease. Part V. Dietary modification. Nutrition Forum 6:33–37, 1989.
  32. Anderson JW and others. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. American Journal of Clinical Nutrition 40:1146–1155, 1984.
  33. Bell LP and others. Cholesterol-lowering effects of psyllium hydrophilic mucilloid-adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA 261:3419–3423, 1989.
  34. Barrett S. Tips for lowering your dietary fat content. Quackwatch Web site, March 31, 2000.
  35. Wolk A and others. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 281:1998–2004, 1999.
  36. Gillman MW and others. Protective effect of fruits and vegetables on development of stroke in men. JAMA 273:1113–1117, 1995.
  37. Joshipura KJ and others. Fruit and vegetable intake in relation to risk of stroke. JAMA 282:1233–1239, 1999.
  38. Ripsin CM. Oat products and lipid lowering: A meta-analysis. JAMA 267:3317–3325, 1992.
  39. Davidson MH and others. The hypocholesterolemic effects of b-glucan in oatmeal and oat bran. JAMA 265:1833–1839, 1991.
  40. Kris-Etherton PM. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747–2757, 2002.
  41. Omega-3 oil. Fish or pills? Consumer Reports 68(7):30–32, 2003.
  42. Milani RV, Lavie CJ. Pharmacologic prevention of coronary artery disease. What do clinical trials show? Postgraduate Medicine 99:109–120, 1996.
  43. Gotto AM Jr. Lipid lowering, regression, and coronary events: A review of the interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 92:646–656, 1995.
  44. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389, 1994.
  45. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274–1275, 1995.
  46. Byington RP and others. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92:2419–2925, 1995.
  47. Gould AL and others. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 91:2274–2282, 1995.
  48. Ornish D and others. Can lifestyle changes reverse coronary heart disease? Lancet 336:129–133, 1990.
  49. Gould KL, Ornish D and others. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. American Journal of Cardiology 69:845–853, 1992.
  50. Gould KL, Ornish D and others. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274:894–901, 1995.
  51. Ornish D and others. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001–2007, 1998.
  52. Pritikin R. The New Pritikin Program: The Easy and Delicious Way to Shed Fat, Lower Your Cholesterol, and Stay Fit. New York, 1990, Simon & Schuster.
  53. New York City Department of Consumer Affairs. Supermarket Survey on Misleading Cholesterol Claims. New York, 1991, The Department.
  54. Drugs for lipids. Treatment Guidelines from The Medical Letter 3:15–22, 2005.
  55. Hodes HN. Acute hepatic failure associated with low-dose sustained-release niacin. JAMA 264:181, 1990.
  56. Henkin Y. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 264:241–243, 1990.
  57. Etchason JA and others. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clinic Proceedings 66:23–28, 1991.
  58. McKenney JM and others. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672–677, 1994.
  59. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. British Medical Journal 308:81–106, 159–168, 235–246, 1994.
  60. Hennekens CH and others. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 96:2751–2753, 1997.
  61. Alder R and others. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. Journal of the American Academy of Nurse Practitioners 15:120–123, 2003.
  62. Hennekens CH and others. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine 334:1145–1149, 1996.
  63. Vivekananthan DP and others. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomized trials. Lancet 361:2017–2023, 2003.
  64. Knuiman A and others. Lecithin intake and serum cholesterol. American Journal of Clinical Nutrition 49:266–268, 1989.
  65. Coenzyme Q10. American Heart Association Web site, accessed May 17, 2005.
  66. Pharmanex v. Shalala, U.S. District Court for the District of Utah, March 30, 2001.
  67. Brobst DE and others. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. Journal of Pharmacology and Experimental Therapeutics 310:528–535, 2004.
  68. Szapary PO and others. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA 290:765–772, 2003
  69. Research news. University of Texas Southwestern Medical Center, Jan 2, 1997.
  70. Gaziano JM and others. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. New England Journal of Medicine 329:1829–1834, 1993.
  71. Friedman GD, Klatsky AL. Is alcohol good for your health? New England Journal of Medicine 329:1882–1883, 1993.
  72. Cholesterol-lowering margarines. The Medical Letter 41:56–58, 1999.
  73. FTC alleges Maryland companies lack support for claims that Heartbar is effective against cardiovascular diseases. FTC news release, June 12, 2003.
  74. FTC puts the squeeze on Tropicana’s orange juice claims. FTC news release, June 2, 2005.
  75. Reeves RA. Does this patient have hypertension? How to measure blood pressure. JAMA 273:1211–1218, 1995.
  76. Vesan RS and others. Residual lifetime risk for developing hypertension in middle-age women and men: The Framingham Heart Study. JAMA 287:103–110, 2002.
  77. Chobanian AV and others. JNC Express: Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md., 2004, National Institutes of Health.
  78. Chobanian AV and others. Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md., 2004, National Institutes of Health.
  79. Pescatello LS and others. American College of Sports Medicine position stand: Exercise and hypertension. Medicine & Science in Sports & Exercise 25:533–553, 2004. [Full text can be accessed by following the links to ACSM position stands.]
  80. Appel LJ and others. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. New England Journal of Medicine 336:1117–1124, 1997.
  81. Sachs FM and others. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. New England Journal of Medicine 344:3–10, 2001.
  82. Aspirin in heart attack and stroke prevention. American Heart Association Web site, accessed May 23, 2005.
  83. When the electrocardiogram is abnormal. Harvard Heart Letter 5(3):1–5, 1994.
  84. Lee TH and others. Coronary Artery Disease: Diagnosis and Treatment. Boston, 1994, Harvard Publications Group.
  85. Gibbons RJ and others. ACC/AHA 2002 guidelines for exercise testing update: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Journal of the American College of Cardiology 40:1531–1540, 2002.
  86. What is an exercise stress test? The Johns Hopkins Medical Letter 3(10):6–7, 1991.
  87. Budoff MJ and others. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation 93:898–904, 1996.
  88. O'Rourke RA and others. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126–140, 2000.
  89. Myers WO and others. CASS Registry long term surgical survival. Coronary Artery Surgery Study. Journal of the American College of Cardiology 33:488–498, 1999.
  90. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. Journal of the American College of Cardiology 35:1122–1129, 2000.
  91. Eagle KA and others. ACC/AHA guidelines for coronary artery bypass graft surgery: Executive summary and recommendations. Circulation 100:1464–1480, 1999.
  92. Farley D. Balloons, lasers and scrapers: Help for hearts and blood vessels. FDA Consumer 25(3):22–27, 1991.
  93. Stent procedure. American Heart Association Web site, accessed May 23, 2005.
  94. American College of Sports Medicine position stand: Exercise for patients with coronary artery disease. Medicine & Science in Sports & Exercise 26(3):i–v, 1994.

This page was revised on October 17, 2005.

Sponsored Links to Recommended Companies